Navigation Links
Kiadis Pharma to Receive GMP Manufacturing License and GMP Certificate
Date:7/22/2013

AMSTERDAM, July 23, 2013 /PRNewswire/ --

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that its Quality Control (QC) laboratory and the associated Quality system has been inspected for good-manufacturing-practice (GMP) by the Dutch Health Care Inspectorate (IGZ) and has fully met the EU GMP standards. As a result, Kiadis Pharma will receive a GMP manufacturing license and GMP certificate for its QC laboratory from the Dutch Ministry of Health, Welfare and Sport.  

GMP licensing and certification enables Kiadis Pharma to perform QC release-assays for the clinical trial manufacturing of the Company's lead product ATIR™, a cellular therapeutic that will enable partially mismatched donor stem cell transplants from family members in blood cancer patients.

Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma, commented: "This is an important milestone for Kiadis Pharma as we are committed to the highest standards of manufacturing. We are delighted that our QC laboratory and the associated Quality system will receive a GMP manufacturing license and GMP certificate. This not only attests to the quality that we have established at Kiadis Pharma, but secures the pathway to take ATIR™ to the next stage of development. ATIR™ is currently in an ongoing Phase II study to confirm and extend some exciting data. We expect the Phase II results in H1 2014."

About ATIR™

ATIR™ is a cell based medicinal product enabling stem cell transplantations using partially mismatched (haploidentical) family members as donors for patients suffering from blood cancer who lack a suitable standard of care matched donor. Stem cell transplantation is the only potentially curative treatment for many patients but a matching donor is available for only half of the patients in need. ATIR™ thus has the potential to address this unmet need and to make stem cell transplantations available for all patients worldwide.

Those T-cells in a haploidentical graft which would cause Graft-versus-Host-Disease (GvHD) are selectively eliminated using proprietary technology to produce ATIR™. ATIR™ is administered as an adjunctive treatment after a haploidentical stem cell transplantation facilitating early immune reconstitution without causing life-threatening (acute) GvHD.

In a Phase I/II study with ATIR™, safety and proof of concept were confirmed in terms of absence of grade III/IV GvHD, reduced rates of infection, reduced Transplant Related Mortality and high Overall Survival.

ATIR™ is currently in Phase II clinical development and has been granted Orphan Drug Designation both in the EU and the USA. In these regions, 20,000 to 25,000 patients a year are unable to find a suitable standard of care matched donor. Together, both regions represent a combined primary market potential of more than EUR 1 billion per year.

About Kiadis Pharma

Kiadis Pharma B.V. is a private, clinical stage biopharmaceutical company developing innovative and potentially life-saving therapies for patients with late stage blood cancers and related disorders who are in need of a transplant, an area of significant unmet medical need.

Kiadis Pharma's lead product is ATIR™, a cell based product currently in Phase II development, which is designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors. Kiadis Pharma is collaborating with internationally renowned centers in Europe and North America for the successful development and manufacturing of ATIR™.

Kiadis Pharma is supported by a strong group of leading international investors including LSP, Alta Partners, DFJ Esprit, Quest for Growth, MedSciences Capital and NOM. Kiadis Pharma is based in Amsterdam, The Netherlands. Further information can be found at: http://www.kiadis.com

Company Contact:
Manfred Ruediger, CEO
Kiadis Pharma
Entrada 231-234
1096 EG AMSTERDAM
The Netherlands
Tel. +31-20-314-02-50
communication@kiadis.com

Media and Investor Contact:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
M:Communications
Tel: +44-(0)207-920-2333
kiadis@mcomgroup.com


'/>"/>
SOURCE Kiadis Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
2. State Exchanges And Other Post-ACA Implementation Hinder 2014 Planning For Pharma
3. CRO Solutions, Inc. Announces Opening of New Division - VxP Pharma Services, Inc.
4. ResearchMoz.us: Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
5. Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
6. ANI Pharmaceuticals, Inc. Announces Date for Second Quarter 2013 Earnings Release
7. QRxPharma Announces Collaboration With Aesica
8. Aquavit Pharmaceuticals and U-Bio Med Enter Exclusive Worldwide License Agreement for Microneedle Technology (AQT-001)
9. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
10. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
11. Todays Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... NEW YORK , Feb. 4, 2016   Bernstein ... has been filed in the United States District Court for ... of a class (the "Class") consisting of all persons or ... or the "Company") (NASDAQ: INSY ) from March 3, ... charges Insys and certain of its officers with violations of ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener Polyangiitis ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline Review, ... Polyangiitis,s therapeutic pipeline. This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ...
(Date:2/4/2016)... Summary Breast cancer, a malignant neoplasm, is the ... in women worldwide, accounting for 16% of all female ... women diagnosed with breast cancer has increased over the ... declined due to earlier diagnosis and better treatment options. ... past four decades, especially with increasing usage of targeted ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth ... country gathered at the La Valencia Hotel in San Diego, California to discuss ... named the year’s most outstanding franchise, walking away with the coveted David Wright ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Give ... allow users to search for and donate to Give To Cure’s campaign that is ... app that lets users make and share payments through a smart device. In 2015 ...
(Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Ben Amini, a ... is now welcoming orthodontist, Dr. Amanda Cheng, to the practice. With the addition ... health care, including general dentistry, cosmetic treatments, periodontics, implant dentistry , endodontics, ...
(Date:2/5/2016)... ... ... Health and wellness is a topic that should concern all Americans; however, it ... illness. Migraines are a severe form of a headache and often are accompanied by ... pain on their worst enemy, the feeling can last for many hours and be ...
Breaking Medicine News(10 mins):